Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials.

@article{Mabilleau2014UseOG,
  title={Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials.},
  author={Guillaume Mabilleau and Aleksandra Mieczkowska and Daniel Chappard},
  journal={Journal of diabetes},
  year={2014},
  volume={6 3},
  pages={260-6}
}
BACKGROUND Patients with type 2 diabetes mellitus (T2DM) are at a higher risk of bone fractures independent of the use of antidiabetic medications. Furthermore, antidiabetic medications could directly affect bone metabolism. Recently, the use of dipeptidyl peptidase-4 inhibitors has been associated with a lower rate of bone fracture. The aim of the present meta-analysis was to assess whether patients with T2DM treated with glucagon-like peptide-1 receptor agonists (GLP-1Ra) present a lower… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
37 Citations
33 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

The PRISMA statement for reporting systematic reviews and meta G. MABILLEAU et al. GLP-1Ra and bone fractures

  • A Liberati, DG Altman, J Tetzlaff
  • 2013
1 Excerpt

Similar Papers

Loading similar papers…